BIOHM Health
- Industry
- Biotechnology
- Founded Year
- 2016
- Headquarters
- Cleveland, Ohio, United States
- Employee Count
- 27
Key People
- Afif Ghannoum - Founder
- Dr. Mahmoud Ghannoum - Co-Founder
- Sam Schatz - CEO
- Kristin Wilhoyte - Vice President of B2B Marketing
- Dr. John Deaton - Vice President of Science and Technology
Assessment
- Team
-
Aspect: Multiple successful MedTech entrepreneurs
Summary: The leadership team comprises experienced professionals with significant expertise in microbiome research and product development.
The founders, Afif and Dr. Mahmoud Ghannoum, bring a wealth of knowledge in microbiome research. CEO Sam Schatz and VP of Science and Technology Dr. John Deaton add further depth with their backgrounds in microbiome innovation and microbial research, respectively.
- Clinical Need
-
Aspect: Very Strong
Summary: There is a significant demand for advanced microbiome solutions to address gut health issues.
Biohm Technologies' approach to integrating bacterial and fungal research offers a comprehensive solution to gut health, meeting a pressing clinical need in the nutraceutical industry.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for microbiome-based products is competitive but offers opportunities for differentiation.
The nutraceutical industry has numerous players in the microbiome space; however, Biohm's emphasis on the fungal aspect of the microbiome sets it apart from competitors.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing effective microbiome products involves moderate technical challenges.
While formulating microbiome products that effectively target both bacteria and fungi presents technical challenges, Biohm's collaboration with institutions like Virginia Tech enhances its capabilities in this area.
- Patent
-
Aspect: Strong
Summary: Biohm holds patents for its microbiome-based products and ingredients.
Holding patents for its products and ingredients provides Biohm with a competitive advantage and protects its innovations in the microbiome space.
- Financing
-
Aspect: Well-funded
Summary: Biohm has secured significant funding from reputable investors.
With a $7.5 million equity financing round in January 2023 and additional investments from firms like Praesidium and Sparkfood by Sonae, Biohm is well-capitalized to advance its research and product development initiatives.
- Regulatory
-
Aspect: 510k/PMA
Summary: Biohm's products are subject to regulatory approvals typical for the nutraceutical industry.
As a company in the nutraceutical sector, Biohm must comply with regulatory standards for its products, which involves obtaining necessary approvals and ensuring product safety and efficacy.
Opportunity Rollup
- Odds of Success
- 4.05
- Peak Market Share
- 5.7
- Segment CAGR
- 6.3%
- Market Segment
- Nutraceuticals
- Market Sub Segment
- Microbiome-based Products
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.29 |
| 2 | 0.86 |
| 3 | 2.00 |
| 4 | 3.99 |
| 5 | 5.70 |
Key Takeaway
Biohm Technologies, with its unique focus on both bacterial and fungal components of the microbiome, is well-positioned to capitalize on the growing demand for gut health solutions in the nutraceutical market.